TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03669510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer guided IAN lateralization surgical technique
Description: Tthe neurosensory alterations with computer guided inferior alveolar nerve lateralization versus non guided classic technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computer guided IAN lateralization surgical technique
Description: Tthe neurosensory alterations with computer guided inferior alveolar nerve lateralization versus non guided classic technique
Study: NCT01791894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV
Study: NCT01493518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 557 or PLACEBO
Description: Multiple subcutaneous doses of AMG 557 or Placebo on Days 1, 8, 15, 29, 43, 57 and 71.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 557 or PLACEBO
Description: Multiple subcutaneous doses of AMG 557 or Placebo on Days 1, 8, 15, 29, 43, 57 and 71.
Study: NCT03669211

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac stress test
Description: In order to assess the evolution of their cardiorespiratory function, patients will benefit from two cardiac stress test combined with VO2 study, one at inclusion in the study, and the other one 6 months later.
Study: NCT00637845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Magnesium
Description: 40mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: 30mg twice daily
Study: NCT01265862

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation through LMA-Fastrach®
Description: Tracheal intubation through a supraglottic airway device (LMA-Fastrach®) using a GlideRite® endotracheal tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation through I-gel®
Description: Tracheal intubation through a supraglottic airway device (I-gel®) using a GlideRite® endotracheal tube
Study: NCT02536092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm and 1064nm Nd:YAG laser
Description: Dual wavelength 755nm and 1064nm Nd:YAG laser
Study: NCT02707484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide (100mg)
Description: Patients were randomly assigned to receive a 120-days course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide (50mg)
Description: Patients were randomly assigned to receive a 120-days course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients were randomly assigned to receive a 120-days course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
Study: NCT03274388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nutritional therapy
Description: protein-rich nutritional therapy and counseling, during study period of 12 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nutritional therapy
Description: protein-rich nutritional therapy and counseling, during study period of 12 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WB-EMS combined with nutritional therapy
Description: protein-rich nutritional therapy and counseling plus whole body electromyostimulation exercise training, twice a week for 20 min., during study period of 12 weeks
Study: NCT02444208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Inhibitory Control Training
Description: Subjects will learn to inhibit responding in the presence of cocaine cues.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Inhibitory Control Training
Description: Subjects will learn to inhibit responding in the presence of neutral cues.
Study: NCT00574704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
Description: subcutaneous injections at 6 visits

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: House dust mite allergen extract in combination with CYT003-QbG10-placebo
Description: subcutaneous injections at 6 visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT003-AllQbG10 in combination with house dust mite allergen extract placebo
Description: subcutaneous injections at 6 visits

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo
Description: subcutaneous injections at 6 visits
Study: NCT02629939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: course for learning CPR
Study: NCT04016675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery
Description: After assigned into the study group, subjects will be conducted with incisional biopsy. Based on the tumor type and tumor stage, subjects will be conducted with neoadjuvant radiotherapy/chemoradiotherapy followed by radical surgery and simultaneous orbital reconstruction. After surgery, adjuvant chemotherapy will be determined based on the tumor histology, local tumor invasiveness, proximity of the surgical margins from the tumor, and pronouncement of tumor margins on permanent section tissue review.
Study: NCT00108355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Description: Octreotide LAR 20 mg intramuscular injection every 30 days
Study: NCT04016675

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy
Description: After assignment into the control group, subjects will receive radical surgery without simultaneous orbital reconstruction. Adjuvant radiotherapy / chemoradiotherapy will initiate within two weeks after surgery. Both the radiotherapy and chemoradiotherapy should be comparable between the study group and the control group when tumor characteristics in these two groups are identical.
Study: NCT00489918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: Macroflux® patch applied to the abdomen for 30 minutes daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: Macroflux® patch applied to the abdomen for 30 minutes daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: Macroflux® patch applied to the abdomen for 30 minutes daily
Study: NCT03801213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: urinary catheterization
Description: Urinary catheterization with pain controlled
Study: NCT00489918

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: teriparatide
Description: Macroflux® patch applied to the abdomen for 30 minutes daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh
Study: NCT03801213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual bladder stimulation technique
Description: manual gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
Study: NCT03842917

Intervention type: OTHER
Intervention: Biological samples
Description: Urine and blood samples

Intervention type: OTHER
Intervention: Blood pressure measurement
Description: Home blood pressure self-measurement and hospital blood pressure measurement
Study: NCT02125682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atovastatin 10 mg/day
Description: patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80 mg/day
Description: patients will receive 80 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 10 mg daily for 8 weeks
Study: NCT00157846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-P or CRT-D Device
Description: Upgrade from ICD or pacemaker to CRT-D/CRT-P (Insync III, Insync Marquis, Insync Sentry, Insync Maximo, Concerto)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-P or CRT-D Device
Description: Upgrade from ICD or pacemaker to CRT-D/CRT-P (Insync III, Insync Marquis, Insync Sentry, Insync Maximo, Concerto)
Study: NCT02594553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GP-parent information-exchange tool
Description: The booklet incorporates already existing information about fever, alarm symptoms, advices use of medication and specific infectious diseases that frequently occur in childhood in combination with fever such as upper respiratory tract infections, and otitis media. The difference with these existing sources of information is the fact that they until now, were not incorporated into one booklet which can be physically handed over to parents.
Study: NCT02556320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-epileptic drug
Description: Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
Study: NCT06490848

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic cerebral angiography
Description: In transradial access, no preprocedural upper extremity collateral blood supply testing was completed. When the radial access is unsuccessful, it is shifted to ulnar or femoral access. All right arms were secured in the fully supine position to allow access to both radial and ulnar arteries. At the conclusion of radial access procedures, a TR band was applied to close the access. Neurological exams as well as radial artery pulse and pulse oximeter of the right first finger were assessed during and on discharge by trained recovery nurses. Femoral access was performed in a standard manner. After the access (femoral or radial), a cerebral angiogram was performed in a standard manner using appropriate catheters (vertebral, bern, Simmons 2 or 3) according to the access. For the radial access, the patient was slightly sedated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic cerebral angiography
Description: In transradial access, no preprocedural upper extremity collateral blood supply testing was completed. When the radial access is unsuccessful, it is shifted to ulnar or femoral access. All right arms were secured in the fully supine position to allow access to both radial and ulnar arteries. At the conclusion of radial access procedures, a TR band was applied to close the access. Neurological exams as well as radial artery pulse and pulse oximeter of the right first finger were assessed during and on discharge by trained recovery nurses. Femoral access was performed in a standard manner. After the access (femoral or radial), a cerebral angiogram was performed in a standard manner using appropriate catheters (vertebral, bern, Simmons 2 or 3) according to the access. For the radial access, the patient was slightly sedated.
Study: NCT04596774

Intervention type: PROCEDURE
Intervention: Traditional Approach
Description: Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.

Intervention type: PROCEDURE
Intervention: Enhanced Recovery After Surgery (ERAS) Approach
Description: Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
Study: NCT00108355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline injection (Octreotide LAR placebo)
Description: Saline intramuscular injection 5 cc every 30 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Volume Paracentesis
Description: Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large Volume Paracentesis
Description: Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
Study: NCT03092856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-OX40 Antibody PF-04518600
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given IV
Study: NCT03525080

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET imagery
Description: Every patients will have a PET imagery in addition to standard MRI
Study: NCT04406883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extraction + filled with Simvastatin solution impregnated gelatin sponge
Description: All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extraction + filled with Simvastatin solution impregnated gelatin sponge
Description: All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.
Study: NCT02344914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: receive Laboraide
Description: After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire.
Study: NCT04297488

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacteria and Lactobacilli triple viable capsules
Description: Bifidobacteria and Lactobacilli triple viable capsules (provided by Shenzhen Wan he Pharmaceutical Co., Ltd., China) are bilayer mini pellets and are resistant to gastric acid. So Bifidobacterium billion Lactobacillus can only be released in intestine. Participants will take 1.27g (contain 3 billion Bifidobacterium and 1 billion Lactobacillus) once daily.
Study: NCT03183973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF
Description: patients who will receive PRF suspension

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo group
Description: patients who will receive Placebo
Study: NCT02149862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine infrared analysis
Description: Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Urine infrared analysis
Description: Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
Study: NCT01777607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPELLA® RP
Study: NCT01178112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trientine
Description: Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trientine MTD
Description: Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trientine MTD
Description: Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trientine MTD
Description: Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin MTD
Description: Maximum tolerated dose found in MTD Dose Escalation Group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin MTD
Description: Maximum tolerated dose found in MTD Dose Escalation Group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin MTD
Description: Maximum tolerated dose found in MTD Dose Escalation Group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PK Testing
Description: Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PK Testing
Description: Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
Study: NCT04106947

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires
Study: NCT02996617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF regimen
Description: Patients weren't preventive use of rhG-CSF.If their WBC≤1×10\^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10\^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF regimen
Description: Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
Study: NCT03304210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Abraxane
Description: Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Abraxane
Description: Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Abraxane
Description: Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Abraxane
Description: Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Abraxane
Description: Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.
Study: NCT04182984

Intervention type: DRUG
Intervention: Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)
Description: Treatment regimens are determined according to the physician's judgment and preferences of the patients.